Skip to content Skip to footer
Subscribe Now
Know Your Investor: Google Ventures
INSIGHTS+

Know Your Investor: Google Ventures

Shots:  An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others  Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…
December 27, 2023

Read more

Disease of the Month - Pancreatic Cancer
INSIGHTS+

Disease of the Month – Pancreatic Cancer

Shots To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic Cancer  November 16th is observed as World Pancreatic Cancer…
December 18, 2023

Read more

Insights+ Key Biosimilars Events of November 2023
INSIGHTS+

Insights+ Key Biosimilars Events of November 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During November, Amgen received US FDA approval for Wezlana, biosimilar of ustekinumab &…
December 6, 2023

Read more

Know Your Investor: Alexandria Venture Investments
INSIGHTS+

Know Your Investor: Alexandria Venture Investments

Shots: Know Your Investor’s November Edition revolves around Alexandria Venture Investments, which dedicatedly invests in the healthcare sector  Established in 1996, Alexandria Venture Investments is based in Pasadena, California, and is the corporate venture capital arm of Alexandria Real Estate Equities In 2022, Alexandria participated in 31 investment rounds, with Affini-T Therapeutics receiving the highest…
November 29, 2023

Read more

Disease of the Month - Ulcerative Colitis
INSIGHTS+

Disease of the Month – Ulcerative Colitis

Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots presents a condensed report on Ulcerative Colitis, which causes inflammation and sores (ulcers) in the digestive…
November 28, 2023

Read more

Top Performing Drug – Cosentyx (November Edition)
INSIGHTS+

Top Performing Drug – Cosentyx (November Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Cosentyx and prepared a curated analysis report for our readers  Cosentyx is indicated for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a human IgG1κ mAb which targets interleukin (IL)-17A    PharmaShots presents a…
November 22, 2023

Read more

Exclusive Webinar Successful Drug Discovery- Collaboration Among Multiple Functions
EVENTS

Exclusive Webinar: Successful Drug Discovery- Collaboration Among Multiple Functions

Join Us for an Illuminating Dive into the Science and Collaboration Driving Innovative Drug Development In the realm of healthcare breakthroughs, modern drug discovery stands at the frontier, blending scientific ingenuity with collaborative prowess. The art of discovering new molecular entities isn't merely a stroke of luck; it's a multifaceted journey, a symphony of disciplines…
November 21, 2023

Read more

New Drug Designations - October 2023
INSIGHTS+

New Drug Designations – October 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA and the EMA. This month’s report includes 2 biological drugs, 12 small molecules, 10 cell and gene therapies, 2 vaccines, 1 peptide, 1 exosome-based therapy and 3 devices  HuidaGene Therapeutics’ HG204 CRISPR RNA-editing therapy, focused on the treatment of MECP2 duplication…
November 20, 2023

Read more

Load more